Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOSCA-5 study of MZ-004 for chronic total coronary occlusions
NL-OMON41937Phase 2Active, not recruiting
- Sponsor
- Matrizyme Pharma
- Start
- Oct 2015
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of collagenase clostridium histolyticum in Chronic coronary occlusion (CTO) (3 arms), sponsored by Matrizyme Pharma. Started Oct 2015; status: active, not recruiting.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
Chronic coronary occlusion (CTO)
Beyond the preview
Go deeper on NL-OMON41937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41937.